High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens

Journal of Experimental Medicine

Volumn 201, Issue 2, 2005, Pages 241-248

  Germeau, Catherine ^a   Ma, Wenbin ^a,b   Schiavetti, Francesca ^a,d   Lurquin, Christophe ^a,b   Henry, Emmanuelle ^a   Vigneron, Nathalie ^a,b   Brasseur, Francis ^a,b   Lethé, Bernard ^a,b   De Plaen, Etienne ^a,b   Velu, Thierry ^c   Boon, Thierry ^a,b   Coulie, Pierre G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 100; MELANOMA ANTIGEN 1; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CLONING; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; MALE; MELANOMA; METASTASIS; PRECURSOR; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR REGRESSION; TUMOR REJECTION; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL COUNT; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 19944434269     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20041379     Document Type: Article

References (29)

1. Chomez, P., O. De Backer, M. Bertrand, E. De Plaen, T. Boon, and S. Lucas. 2001. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61:5544-5551.
2. Boël, P., C. Wildmann, M.-L. Sensi, R. Brasseur, J.-C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2:167-175.
3. De Backer, O., K.C. Arden, M. Boretti, V. Vantomme, C. De Smet, S. Czekay, C.S. Viars, E. De Plaen, F. Brasseur, P. Chomez, et al. 1999. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res. 59:3157-3165.
4. Lethé, B., S. Lucas, L. Michaux, C. De Smet, D. Godelaine, A. Serrano, E. De Plaen, and T. Boon. 1998. LAGE-1, a new gene with tumor specificity. Int. J. Cancer. 76:903-908.
5. Chen, Y.-T., M.J. Scanlan, U. Sahin, Ö. Türeci, A.O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L.J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA. 94:1914-1918.
6. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269:1281-1284.
7. Brichard, V., A. Van Pel, T. Wölfel, C. Wölfel, E. De Plaen, B. Lethé, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489-495.
8. Coulie, P.G., V. Brichard, A. Van Pel, T. Wölfel, J. Schneider, C. Traversari, S. Mattel, E. De Plaen, C. Lurquin, J.-P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35-42.
9. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.R. Yannelli, E. Appella, and S.A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.
10. Bakker, A.B.H., M.W.J. Schreurs, A.J. de Boer, Y. Kawakami, S.A. Rosenberg, G.J. Adema, and C.G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005-1009.
11. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dréno, M.-H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80:219-230.
12. Marchand, M., C.J.A. Punt, S. Aamdal, B. Escudier, W.H.J. Kruit, U. Keilholz, L. Håkansson, N. van Baren, Y. Humblet, P. Mulders, et al. 2003. Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: clinical report. Eur. J. Cancer. 39:70-77.
13. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, et al. 1999. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669-1678.
14. Schuler-Thurner, B., E.S. Schultz, T.G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P.O. Fritsch, N. Romani, and G. Schuler. 2002. Rapid induction of tumor-specific type I T helper cells in metastatic melanoma patients by vaccination with mature, cryo-preserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195:1279-1288.
15. Coulie, P.G., V. Karanikas, D. Colau, C. Lurquin, C. Landry, M. Marchand, T. Dorval, V. Brichard, and T. Boon. 2001. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA. 98:10290-10295.
16. Lonchay, C., P. van der Bruggen, T. Connerotte, T. Hanagiri, P. Coulie, D. Colau, S. Lucas, A. Van Pel, K. Thielemans, N. van Baren, and T. Boon. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA. 101:14631-14638.
17. Karanikas, V., C. Lurquin, D. Colau, N. van Baren, C. De Smet, B. Lethé, T. Connerotte, V. Corbière, M.-A. Demoitié, D. Liénard, et al. 2003. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J. Immunol. 171:4898-4904.
18. Lurquin, C., B. Lethé, V. Corbière, I. Théate, N. van Baren, P.G. Coulie, and T. Boon. 2004. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201:249-257.
19. Coulie, P.G., M. Somville, F. Lehmann, P. Hainaut, F. Brasseur, R. Devos, and T. Boon. 1992. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer. 50:289-297.
20. Lucas, S., E. De Plaen, and T. Boon. 2000. MAGE-B5, MAGE-B6, MAGE-C2 and MAGE-3: four new members of the MAGE family with tumor-specific expression. Int. J. Cancer. 87:55-60.
21. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P.P. Robbins, A. Sette, E. Appella, and S.A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961-3968.
22. Ma, W., C. Germeau, N. Vigneron, A.-S. Maernoudt, S. Morel, T. Boon, P.G. Coulie, and B. Van den Eynde. 2004. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int. J. Cancer. 109:698-702.
23. Khong, H.T., and N.P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3:999-1005.
24. Lee, P.P., C. Yee, P.A. Savage, L. Fong, D. Brockstedt, J.S. Weber, D. Johnson, S. Swetter, J. Thompson, P.D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-685.
25. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64:2865-2873.
26. Dreno, B., J.M. Nguyen, A. Khammari, M.C. Pandolfino, M.H. Tessier, S. Bercegeay, A. Cassidanius, P. Lemarre, S. Billaudel, N. Labarrière, and F. Jotereau. 2002. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol. Immunother. 51:539-546.
27. Dudley, M.E., J. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
28. Herr, W., T. Wölfel, M. Heike, K.H. Meyer zum Büschenfelde, and A. Knuth. 1994. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol. Immunother. 39:93-99.
29. Mazzocchi, A., F. Belli, L. Mascheroni, C. Vegetti, G. Parmiani, and A. Anichini. 1994. Frequency of cytotoxic T-lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int. J. Cancer. 58:330-339.